title: [Alternation of proteins in brain of Parkinson's disease model rats after the transplantation of TH-NTN gene modified bone marrow mesenchymal stem cells].
abstract: OBJECTIVE
  To explore the effects of tyrosine hydroxylase-neurturin (TH-NTN) gene modified bone marrow mesenchymal stem cell (BMSC) transplantation in Parkinson's disease (PD) model rats and the alternations of correlated proteins.
  
  
  METHODS
  The PD rat model was established by the 2-point injection of 6-hydroxydopamine (6-OHDA) into unilateral (right) striatum. Successful modeling rats were separated into PD, BMSC and TH-NTN-BMSC groups. BMSC and TH-NTN-BMSC groups were transplanted into BMSCs and TH-NTN gene modified BMSC cells separately into right striatum. After transplantation, ethology detection in all groups was made with an intraperitoneal injection of apomorphine (APO). Dopamine (DA) and Dihydroxyphenylacetic Acid (DOPAC) in striatum were detected by high performance liquid electrochemical analysis. TH and NTN proteins in right striatum were also analyzed by immunohistochemistry and Western blot. Finally the density of dopamine receptors in post synaptic density of dopaminergic synapses of corpus striatum were compared between each group by post-embedding immunogold electron microscopy.
  
  
  RESULTS
  After an injection of APO, rotation frequency decreased in TH-NTN-BMSC group, i.e. (5.7 ± 1.3) circles/min versus (10.8 ± 2.2), (9.9 ± 1.2) circles/min in PD and BMSC groups (P < 0.05). For proteins in right striatum, DA, (0.421 ± 0.113) and DOPAC, (0.093 ± 0.012) nmol/L increased significantly versus (0.208 ± 0.043), (0.043 ± 0.017) nmol/L in PD and (0.231 ± 0.082), (0.044 ± 0.023)noml/L in BMSC groups (P < 0.05). Also a lower density of D2 receptors at (623 ± 96)/µm(2) in TH-NTN-BMSC group versus (923 ± 132)/µm(2) in PD and (860 ± 116)/µm(2) in BMSC groups was also found.
  
  
  CONCLUSIONS
  The combined therapy of TH and NTN genes increases the synthesis of DA and also protects the dopaminergic neurons to achieve double therapeutic effects. It may provide potential innovations of PD genetic therapy.
authors.affiliation: Department of Neurology, Henan Provincial People's Hospital, Henan, Zhengzhou, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Huang
authors.forename: Cheng
authors.initials: C
authors.lastname: Chang
authors.forename: Jie-wen
authors.initials: JW
authors.lastname: Zhang
authors.forename: Xiao-qun
authors.initials: XQ
authors.lastname: Gao
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation; D001921:Brain / Q000378:metabolism*; D004195:Disease Models, Animal; D015316:Genetic Therapy; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D051101:Neurturin / Q000235:genetics; D010300:Parkinson Disease / Q000378:metabolism* / Q000473:pathology / Q000601:surgery*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics
chemical_list: D051101:Neurturin; D014446:Tyrosine 3-Monooxygenase